Boyce Sarah bought RNA
September 5, 2025 · Form 4 insider transaction
Boyce Sarah bought 50,000 shares of Atrium Therapeutics, Inc. at $1.24 per share, a transaction worth $62.0K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
50,000
Price
$1.24
Total value
$62.0K
InsiderBoyce Sarah
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateSeptember 5, 2025
Filing dateSeptember 5, 2025
Shares owned after355,871
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person.